S'abonner

Effect of Pharmacological Treatment of Attention-Deficit/Hyperactivity Disorder on Criminality - 26/03/24

Doi : 10.1016/j.jaac.2023.05.025 
Tarjei Widding-Havneraas, MPhil a, b, , Henrik Daae Zachrisson, PhD d, Simen Markussen, PhD e, Felix Elwert, PhD f, Ingvild Lyhmann, CandPsychol a, b, Ashmita Chaulagain, MPH a, b, Ingvar Bjelland, MD, PhD a, b, Anne Halmøy, MD, PhD a, b, Knut Rypdal, CandJur a, Arnstein Mykletun, PhD a, b, c
a Haukeland University Hospital, Bergen, Norway 
b University of Bergen, Bergen, Norway 
c Norwegian Institute of Public Health, Oslo, Norway; University of Tromsø, Tromsø, Norway; and Nordland Hospital, Bodø, Norway 
d University of Oslo, Oslo, Norway 
e Ragnar Frisch Centre for Economic Research, Oslo, Norway 
f University of Wisconsin-Madison, Madison, Wisconsin 

Correspondence to Tarjei Widding-Havneraas, MPhil, Haukeland University Hospital, Sandviksleitet 1, 5036 BergenHaukeland University HospitalSandviksleitet 1Bergen5036

Abstract

Objective

Criminality rates are higher among persons with attention-deficit/hyperactivity disorder (ADHD), and evidence that medication reduces crime is limited. Medication rates between clinics vary widely even within universal health care systems, partly because of providers’ treatment preferences. We used this variation to estimate causal effects of pharmacological treatment of ADHD on 4-year criminal outcomes.

Method

We used Norwegian population-level registry data to identify all unique patients aged 10 to 18 years diagnosed with ADHD between 2009 and 2011 (n = 5,624), their use of ADHD medication, and subsequent criminal charges. An instrumental variable design, exploiting variation in provider preference for ADHD medication between clinics, was used to identify causal effects of ADHD medication on crime among patients on the margin of treatment, that is, patients who receive treatment because of their provider’s preference.

Results

Criminality was higher in patients with ADHD relative to the general population. Medication preference varied between clinics and strongly affected patients’ treatment. Instrumental variable analyses supported a protective effect of pharmacological treatment on violence-related and public-order−related charges with numbers needed to treat of 14 and 8, respectively. There was no evidence for effects on drug-, traffic-, sexual-, or property-related charges.

Conclusion

This is the first study to demonstrate causal effects of pharmacological treatment of ADHD on some types of crimes in a population-based natural experiment. Pharmacological treatment of ADHD reduced crime related to impulsive-reactive behavior in patients with ADHD on the margin of treatment. No effects were found on crimes requiring criminal intent, conspiracy, and planning.

Study preregistration information

The ADHD controversy project: Long-term effects of ADHD medication; www.isrctn.com/; 11891971.

Le texte complet de cet article est disponible en PDF.

Key words : ADHD, pharmacological treatment, quasi-experiment


Plan


 TW is supported by funding from the Western Norway Regional Health Authority (912197), Research Council of Norway (288585/IAR), and Centre for Research and Education in Forensic Psychiatry, Haukeland University Hospital. HZ, SM, FE, IL, and AC were supported by Research Council Norway (288585/IAR). AM is supported by Research Council Norway (288585/IAR) and Centre for Research and Education in Forensic Psychiatry, Haukeland University Hospital. HZ is also supported by funding from the European Research Council Consolidator Grant ERC-CoG-2018 EQOP [grant number 818425].
 The research was performed with permission from the Regional Committees for Medical and Health Research Ethics.
 This work has been prospectively registered: ISRCTN11891971.
 Statistical experts for this research: Dr. Markussen is an econometrician. Prof. Elwert is a sociologist and statistician. Prof. Zachrisson is a methodologist with expertise in causal inference.
 Author Contributions
TW: Conceptualization, methodology, data curation, formal analysis, visualization, funding acquisition, project administration, writing-original draft, writing-review & editing. HZ: Conceptualization, supervision, methodology, writing-review & editing. SM: Conceptualization, supervision, methodology, writing-review & editing. FE: Conceptualization, methodology, writing-review & editing. IL: writing-review & editing. AC: writing-review & editing. IB: Conceptualization, supervision, writing-review & editing. AH: Conceptualization, supervision, writing-review & editing. KR: Conceptualization, writing-review & editing. AM: Conceptualization, funding acquisition, methodology, supervision, project administration, writing-review & editing.
 Disclosure: Prof. Zachrisson, Dr. Markussen, Profs. Elwert and Bjelland, Dr. Halmøy, Prof. Mykletun, Mr. Widding-Havneraas, Mss. Lyhmann and Chaulagain, and Mr. Rypdal have reported no biomedical financial interests or potential conflicts of interest.


© 2023  American Academy of Child and Adolescent Psychiatry. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 63 - N° 4

P. 433-442 - avril 2024 Retour au numéro
Article précédent Article précédent
  • Inequities in Mental Health Services: A 16-Year Longitudinal Study of Youth in the Justice System
  • María José Luna, Karen M. Abram, David A. Aaby, Leah J. Welty, Linda A. Teplin
| Article suivant Article suivant
  • The Prognostic Usefulness of Multiple Specifiers for Subtyping Conduct Problems in Early Childhood
  • Olivier F. Colins, Laura López-Romero, Estrella Romero, Henrik Andershed

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.